Čšerk of the House of Representatives Legislative Resource Center 8-106 Casnon Building Wastungton, DC 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

SECRETARY OF THE SENATE OF FEB 14 PM 2: 38

LOBBYING REPORT

· Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

······································		
S. Regismani Address There if different than previously reported Address 412 First Street SE Suite 100 City Washington State/Zip (or County)	DC 20003	
R. Principal Place of Business (if different from tine 2)		
City State/Zip (or Country)		
i. Contact Name E-ma : Arthur Silverman	ë (optional) -	5 Senate IO 9 12868-1680
7 Caent Name 11 Self Biotech Research & Development Cir		6. Rause (3) of 32229103
		11. No Lobbying Activit
Check if this is a Termination Report (>> Termination COME OF EXPENSISE (11. No Lobbying Activity
 Check if this is a Termination Report	r Line 12 OR Line 13	11. No Lobbying Activity
INCOME OR EXPENSES - Complete Either 12. Labbying Firms INCOME relating to labbying activities for this reporting	r Line 12 OR Line 13 13. Orga EXPENSES relating to lobbying	anisations
INCOME OR EXPENSES - Complete Eithe 12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was:	r Line 12 OR Line 13 13. Orga EXPENSES relating to lobbying period were:	anisations
INCOME OR EXPENSES - Complete Eithe 12. Lobbying Firms INCOME relating to tobbying activities for this reporting period was: Less than \$10,009	r Line 12 OR Line 13 13. Orga EXPENSES relating to lobbying	anisations
INCOME OR EXPENSES - Complete Eithe 12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 STE 000 00	r Line 12 OR Line 13 13. Orga EXPENSES relating to lobbying period were: Less than \$10,000 (2)	anisations
INCOME OR EXPENSES - Complete Eithe 12. Labbying Firms INCOME relating to labbying activities for this reporting seriod was: Less than \$10,000 \(\text{L} \) 510,000 or more \(\text{X} \) >> \$\(\text{S75,000.00} \) Income (nearest \$20,000) Provide a good faith estimate, rounded to the nearest	r Line 12 OR Line 13 13. Orga EXPENSES relating to lobbying period were: Less than \$10,000 (2)	enistations activities for this reporting Expenses (neares) \$20,000; Check box to indicate expense
INCOME OR EXPENSES - Complete Eithe 12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was: Less than \$10,000	T Line 12 OR Line 13 13. Orga EXPENSES relating to lobbying period were: Less than \$10,000 (\$10,000 or more \$10,000 or mor	enistations activities for this reporting Expenses (neares) \$20,000; Check box to indicate expense
INCOME OR EXPENSES - Complete Eithe 12. Lobbying Firms INCOME relating to tobbying activities for this reporting period was: Loss than \$10,000	The 12 OR Line 13 13. Orga EXPENSES relating to lobbying period were: Less than \$10,000 () \$10,000 or more () >> \$ 14. REPORTING METHOD, accounting method. See instruction Method A. Reporting amounting amounting method.	Expenses (nearest \$20.000); Check box to indicate expense ons for description of options, ats using LDA definitions only into under section 6033(b)(8) of
INCOME OR EXPENSES - Complete Eithe 12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was: Less than \$10,000	T Line 12 OR Line 13 13. Orga EXPENSES relating to lobbying period were: Less than \$10,000 (Expenses (nearest \$20,000); Check box to indicate expense ons for description of options, into using LDA definitions only into under section 6033(b)(8) of entire Code into under section 162(e) of the

egistrant Name:	The Dutke Group, Inc.		
liont Name:	Biotech Research & Development Ctr		
ngaged in lobbyii	TVITY. Select as many codes as necessaring on behalf of the client during the report wested. Attach additional page(s) as needed	ry to reflect the general issue areas in which the registrant ting period. Using a separate page for each code, provide ed.	
5. General issue	area code BUD (onc per page)	
6. Specific Lobi			
Secure leder	al appropriations to further biotech res	search and development	
	Congress and Federal agencies contacted presentatives	C) Check if None	
Senate			
8. Name of cacl	a individual who acted as a tobbyist in this	s issue area	
 Name of cacl Name 	a individual who acted as a tobbyist in this	Covered Official Position (if applicable)	New
	n individual who acted as a tobbyist in this	:	<u> </u>
Name Irion, Mark	· · · · · · · · · · · · · · · · · · ·	Covered Official Position (if applicable)	No
Name	· · · · · · · · · · · · · · · · · · ·	Covered Official Position (if applicable)	<u> </u>
Name Irion, Mark	· · · · · · · · · · · · · · · · · · ·	Covered Official Position (if applicable)	No
Name Irion, Mark	· · · · · · · · · · · · · · · · · · ·	Covered Official Position (if applicable)	No
Name Irion, Mark	· · · · · · · · · · · · · · · · · · ·	Covered Official Position (if applicable)	No
Name Irion, Mark	· · · · · · · · · · · · · · · · · · ·	Covered Official Position (if applicable)	No
Name Irion, Mark	· · · · · · · · · · · · · · · · · · ·	Covered Official Position (if applicable)	No
Name Irion, Mark	· · · · · · · · · · · · · · · · · · ·	Covered Official Position (if applicable)	No
Name Irion, Mark Simmons, W	Tiliam	Covered Official Position (if applicable)	No
Name Irion, Mark Simmons, W	· · · · · · · · · · · · · · · · · · ·	Covered Official Position (if applicable)	No
Name Irion, Mark Simmons, W	Tiliam	Covered Official Position (if applicable)	No
Name Irion, Mark Simmons, W	Tiliam	Covered Official Position (if applicable)	No